Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ruxolitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 known ✓ | O60674 | 14/20 | 1.00 |
| ▸ | JAK1 known ✓ | P23458 | 12/20 | 1.00 |
| ▸ | JAK3 known ✓ | P52333 | 4/20 | 1.00 |
| ▸ | TYK2 known ✓ | P29597 | 2/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.90 |
| ▸ | PAK4 | O96013 | 2/20 | 0.90 |
| ▸ | ABL1 | P00519 | 2/20 | 0.90 |
| ▸ | RET | P07949 | 2/20 | 0.90 |
| ▸ | LTK | P29376 | 2/20 | 0.90 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.90 |
| ▸ | CLK2 | P49760 | 2/20 | 0.90 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.90 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.90 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.90 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.90 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.90 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.90 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.90 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.90 |
| ▸ | CAMK1D | Q8IU85 | 2/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ruxolitinib SCHEMBL31073616 | 1.00 | JAK2 (1.00) | JAK2JAK1JAK3TYK2DAPK3 | |
| Ruxolitinib SCHEMBL29677819 | 1.00 | JAK2 (1.00) | JAK2JAK1JAK3TYK2DAPK3 | |
| Ruxolitinib SCHEMBL1369365 | 1.00 | JAK2 (1.00) | JAK2JAK1JAK3TYK2DAPK3 | |
| Ruxolitinib SCHEMBL29357426 | 1.00 | JAK2 (1.00) | JAK2JAK1JAK3TYK2DAPK3 | |
| Phosphoric Acid SCHEMBL20474415 | 0.96 | JAK2 (0.93) | JAK2JAK1JAK3TYK2DAPK3 | |
| Phosphoric Acid SCHEMBL3001694 | 0.96 | JAK2 (0.93) | JAK2JAK1JAK3TYK2DAPK3 | |
| Ruxolitinib SCHEMBL101279 | 0.95 | JAK2 (1.00) | JAK2JAK1JAK3TYK2DAPK3 | |
| Ruxolitinib SCHEMBL31247553 | 0.95 | JAK2 (1.00) | JAK2JAK1JAK3TYK2DAPK3 | |
| Ruxolitinib SCHEMBL29677353 | 0.95 | JAK2 (1.00) | JAK2JAK1JAK3TYK2DAPK3 | |
| Ruxolitinib SCHEMBL171319 | 0.95 | JAK2 (1.00) | JAK2JAK1JAK3TYK2DAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215005-A1 | PROCESS FOR PREPARATION OF RUXOLITINIB | ALIVUS LIFE SCIENCES LIMITED (IN) | 2025-07-03 | — | — | US | claimed |
| US-12268681-B2 | Methods of treating myeloproliferative neoplasms | KARTOS THERAPEUTICS, INC. (US) | 2025-04-08 | — | — | US | claimed |
| US-20240293411-A1 | COMBINATION THERAPY COMPRISING JAK PATHWAY INHIBITOR AND ROCK INHIBITOR | INCYTE CORPORATION | 2024-09-05 | — | — | US | claimed |
| CN-117120055-A | Combination therapy comprising a JAK pathway inhibitor and a ROCK inhibitor | 因赛特公司 | 2023-11-24 | — | — | CN | claimed |
| WO-2023223253-A1 | PROCESS FOR PREPARATION OF RUXOLITINIB | GLENMARK LIFE SCIENCES LIMITED (IN) | 2023-11-23 | — | — | WO | claimed |
| EP-4274578-A1 | COMBINATION THERAPY COMPRISING JAK PATHWAY INHIBITOR AND ROCK INHIBITOR | Incyte Corporation (US) | 2023-11-15 | — | — | EP | claimed |
| US-20220226327-A1 | COMBINATION THERAPY COMPRISING JAK PATHWAY INHIBITOR AND ROCK INHIBITOR | INCYTE CORPORATION | 2022-07-21 | — | — | US | claimed |
| WO-2022150676-A1 | COMBINATION THERAPY COMPRISING JAK PATHWAY INHIBITOR AND ROCK INHIBITOR | INCYTE CORPORATION (US) | 2022-07-14 | — | — | WO | claimed |
| CN-111494386-A | Treatment of B cell malignancies by combination of JAK and PI3K inhibitors | 因赛特公司 | 2020-08-07 | — | — | CN | claimed |
| EP-3495369-A1 | USE OF SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H- PYRAZOL-1-YL)-3- CYCLOPENTYLPROPANENITRILE | Incyte Holdings Corporation (US) | 2019-06-12 | — | — | EP | claimed |
| CN-103524509-B | The salt of Zhan Nasi kinase inhibitor (R)-3-(4-(7H-pyrrolo-[2,3-d] pyrimidine-4-yl)-1H-pyrazol-1-yl)-3-cyclopentyl propionitrile | Because of C1-esteraseremmer-N parent corporation (US) | 2016-03-02 | — | — | CN | claimed |
| CN-103524509-A | Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile | INCYTE CORP | 2014-01-22 | — | — | CN | claimed |
| CN-101932582-B | Salts of the janus kinase inhibitor -3- (4- (7H-pyrrolo [2,3-d ] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-cyclopentylpropanenitrile | INCYTE CORP | 2013-09-25 | — | — | CN | claimed |
| CN-101932582-A | Salts of the janus kinase inhibitor -3- (4- (7H-pyrrolo [2,3-d ] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-cyclopentylpropanenitrile | INCYTE CORP | 2010-12-29 | — | — | CN | claimed |
| US-12622908-B2 | Topical formulation for a JAK inhibitor | INCYTE CORPORATION (US) | 2026-05-12 | — | — | US | disclosed |
| US-12564593-B2 | Topical formulation for a JAK inhibitor | INCYTE CORPORATION (US) | 2026-03-03 | — | — | US | disclosed |
| US-12544381-B2 | Topical formulation for JAK inhibitor | INCYTE CORPORATION (US) | 2026-02-10 | — | — | US | disclosed |
| WO-2011146808-A2 | TOPICAL FORMULATION FOR A JAK INHIBITOR | INCYTE CORPORATION (US) | 2011-11-24 | — | — | WO | disclosed |
| CN-101932582-A | Salts of the janus kinase inhibitor -3- (4- (7H-pyrrolo [2,3-d ] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-cyclopentylpropanenitrile | INCYTE CORP | 2010-12-29 | — | — | CN | disclosed |
| US-20100190981-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE CORPORATION | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622908-B2 | Topical formulation for a JAK inhibitor | JAK1, JAK3, JAK2 | JAK2 3/4885JAK1 1/4885JAK3 2/4885 |
| US-12268681-B2 | Methods of treating myeloproliferative neoplasms | JAK2, JAK1, PDPK1 | JAK2 1/4885JAK1 2/4885JAK3 19/4885 |
| US-12544381-B2 | Topical formulation for JAK inhibitor | JAK1, JAK3, STAT6 | JAK2 4/4885JAK1 1/4885JAK3 2/4885 |
| US-20250215005-A1 | PROCESS FOR PREPARATION OF RUXOLITINIB | JAK2, JAK3, JAK1 | JAK2 1/4885JAK1 3/4885JAK3 2/4885 |
| US-20240293411-A1 | COMBINATION THERAPY COMPRISING JAK PATHWAY INHIBITOR AND ROCK INHIBITOR | JAK1, ROCK1, JAK3 | JAK2 8/4885JAK1 1/4885JAK3 3/4885 |
| US-20220226327-A1 | COMBINATION THERAPY COMPRISING JAK PATHWAY INHIBITOR AND ROCK INHIBITOR | JAK1, ROCK1, JAK3 | JAK2 8/4885JAK1 1/4885JAK3 3/4885 |
| US-20100190981-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | JAK3, JAK1, JAK2 | JAK2 3/4885JAK1 2/4885JAK3 1/4885 |
| US-12564593-B2 | Topical formulation for a JAK inhibitor | JAK1, JAK3, DGKK | JAK2 6/4885JAK1 1/4885JAK3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.